Short Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Decreases By 10.6%

Delcath Systems, Inc. (NASDAQ:DCTH) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 1,350,000 shares, a decline of 10.6% from the November 30th total of 1,510,000 shares. Based on an average daily volume of 371,800 shares, the days-to-cover ratio is currently 3.6 days.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DCTH. Point72 Asia Singapore Pte. Ltd. bought a new stake in Delcath Systems in the 3rd quarter valued at $102,000. Barclays PLC acquired a new stake in shares of Delcath Systems during the 3rd quarter valued at about $104,000. Jane Street Group LLC bought a new stake in Delcath Systems in the third quarter valued at about $110,000. Riverwater Partners LLC bought a new stake in Delcath Systems in the third quarter valued at about $161,000. Finally, Virtu Financial LLC acquired a new position in Delcath Systems in the third quarter worth about $289,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Stock Up 1.3 %

Delcath Systems stock traded up $0.15 during trading hours on Wednesday, hitting $12.04. The stock had a trading volume of 214,022 shares, compared to its average volume of 286,478. Delcath Systems has a fifty-two week low of $3.70 and a fifty-two week high of $13.30. The company has a market cap of $384.97 million, a PE ratio of -8.92 and a beta of 0.85. The company has a 50-day moving average of $11.00 and a two-hundred day moving average of $9.53.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on DCTH shares. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. Canaccord Genuity Group reissued a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Delcath Systems in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $21.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.